# Windlas Biotech Ltd (WINDLAS)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹782.35
Day Change: -1.97%
52W High: ₹1095
52W Low: ₹699.35
Market Cap: ₹1,647 Cr

## Valuation
P/E: 24.81
P/B: 3.07
EPS: ₹31.45
Book Value: ₹254.44
Dividend Yield: 0%

## Returns
1Y Return: -7.49%

## Profitability
ROE: 0%
ROCE: 20.97%
Debt/Equity: 0.06
Revenue Growth: 19.5%
Profit Growth: -4.5%
EBITDA Margin: 12.5%
Operating Margin: 7.16%

## About
Windlas Biotech Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Windlas Biotech Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Submission Of Post Buyback Public Announcement
- Announcement: Board Meeting Intimation for Notice Of The Board Meeting Scheduled To Be Held On Thursday, May 21, 2026
- BSE Filing: Submission Of Post Buyback Public Announcement

## Access
Current tier: anonymous
More history: Register free to see 5 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:06.460Z
Price History Updated: 2026-05-18T22:59:00.051Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:59:00.051Z
Quant Updated: 2026-05-18T22:59:00.051Z
Sentiment Updated: 2026-05-18T22:59:00.051Z
Financials Status: current
Financials Updated: 2026-05-18T17:31:59.261Z
Financials Last Attempt: 2026-05-18T17:31:59.261Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2019)
Revenue: ₹352 Cr
Operating Profit: ₹39 Cr (OPM 11%)
Net Profit: ₹11 Cr
Tax: ₹20 Cr

## Annual P&L History
Mar 2019: Rev ₹352Cr | PAT ₹11Cr | OPM 11%
Mar 2020: Rev ₹307Cr | PAT ₹64Cr | OPM 12%
Mar 2021: Rev ₹329Cr | PAT ₹16Cr | OPM 10%

## Balance Sheet (Mar 2019)
Total Assets: ₹290 Cr
Total Liabilities: ₹290 Cr
Borrowings: ₹57 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Komal  Gupta, CFO & CEO
- Ananta Narayan Panda, Company Secretary & Compliance Officer
- Ashok Kumar Windlass, Whole-Time Director
- Hitesh  Windlass, MD & Executive Director
- Manoj Kumar Windlass, Joint MD & Executive Director

---
Source: rupiya.io/stocks/windlas
Disclaimer: For research and education only. Not investment advice.